The PD-L1 genetic test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to evaluate the expression of the Programmed Death-Ligand 1 (PD-L1) gene. PD-L1 is a protein that plays a crucial role in suppressing the immune system, particularly in the context of cancer, by interacting with the PD-1 receptor on T cells. This interaction helps cancer cells evade immune detection and destruction. The test is particularly valuable for patients with certain types of cancer, as it helps oncologists determine the likelihood of response to immunotherapy treatments targeting the PD-1/PD-L1 pathway.
The process involves analyzing a sample of the patient's tumor tissue to measure the level of PD-L1 expression. High levels of PD-L1 may indicate that the patient is more likely to benefit from PD-1/PD-L1 inhibitor therapies, which can block this interaction and enhance the immune system's ability to fight cancer.
At DNA Labs UAE, the PD-L1 genetic test is conducted with precision and care, ensuring reliable results for patients and their healthcare providers. The cost of the test is 8400 AED, reflecting the sophisticated technology and expertise required to perform this advanced genetic analysis. By offering this test, DNA Labs UAE plays a crucial role in the personalized treatment of cancer, enabling more targeted and effective therapies based on the genetic profile of each patient's tumor.
The Oncopro Comprehensive Cancer Panel 161 Genes Test, available at DNA Labs UAE, is a sophisticated diagnostic tool designed to offer a detailed genetic analysis relevant to a wide range of cancers. Priced at 8400 AED, this test screens for mutations in 161 genes associated with increased cancer risk, aiding in the early detection and personalized treatment planning for patients. By analyzing an individual's genetic makeup, healthcare professionals can identify specific genetic mutations that may contribute to the development and progression of cancer. This information is crucial for crafting targeted therapy plans, making risk assessments, and implementing preventive measures for individuals at heightened risk. Conducted in the advanced facilities of DNA Labs UAE, this comprehensive panel is a pivotal step towards personalized medicine in oncology, offering hope for more effective and tailored cancer care strategies.
The HLA Single Antigen Bead (SAB) assay for Class I and II IgG antibodies, commonly referred to as the DSA-SAB Class I and II Test, is a sophisticated diagnostic tool used in immunology and transplant medicine. This assay is designed to detect and identify specific donor-specific antibodies (DSAs) against HLA Class I and Class II antigens in patients who have received or are planning to receive organ transplants. The presence of these antibodies can significantly impact the success of transplantation, as they are associated with acute and chronic rejection of the transplanted organ.
The test utilizes a flow cytometry-based method, where beads coated with purified HLA antigens are mixed with a sample of the patient's serum. If the serum contains antibodies against the HLA antigens present on the beads, they will bind to the beads. The bound antibodies are then detected using a fluorescently labeled anti-human IgG antibody, and the fluorescence intensity is measured. This method allows for the precise identification of the HLA antibodies present, enabling clinicians to make informed decisions regarding transplant compatibility and the management of immunosuppressive therapies.
The DSA-SAB Class I and II Test is available at DNA Labs UAE, a leading diagnostic and research facility in the United Arab Emirates. The test is priced at 9830 AED, reflecting the advanced technology and expertise required to perform this detailed analysis. This assay plays a critical role in transplant immunology, helping to increase the success rates of organ transplants by guiding the selection of compatible donors and tailoring immunosuppressive treatment to minimize the risk of rejection.
The "Prenatal Diagnosis Panel 1 Chorionic Villus Biopsy Test" is a sophisticated diagnostic procedure offered by DNA Labs UAE, aimed at expectant parents who wish to assess the genetic health of their fetus early in the pregnancy. Priced at 9360 AED, this test involves collecting a small sample of chorionic villi, which are tiny finger-like projections found on the placenta. The sample is then analyzed to detect any chromosomal abnormalities or genetic disorders in the fetus, such as Down syndrome, cystic fibrosis, or sickle cell anemia, among others.
Performed between the 11th and 14th weeks of pregnancy, this invasive procedure is recommended for those with a high risk of genetic disorders, including families with a history of genetic conditions, parents with chromosomal abnormalities, or older mothers. Despite its invasive nature, the test provides highly accurate and early insights into the fetus's genetic health, enabling informed decisions and preparations for the future. DNA Labs UAE ensures the procedure is conducted with the utmost care and precision, leveraging advanced technologies and expertise to minimize risks and provide comprehensive support to the expectant parents.
The CLL NGS Panel FISH, KT, IGVH Mutation Analysis, and NGS TP53 Mutation Analysis Test is a comprehensive diagnostic examination offered by DNA Labs UAE, designed specifically for patients suspected of having Chronic Lymphocytic Leukemia (CLL). This test employs advanced Next-Generation Sequencing (NGS) technology, Fluorescence In Situ Hybridization (FISH) techniques, Karyotyping (KT), and IGVH mutation analysis to provide a detailed genetic profile of the CLL. Additionally, it includes an NGS-based TP53 mutation analysis, which is crucial for understanding the disease's prognosis and guiding treatment decisions.
The test aims to identify genetic mutations and chromosomal abnormalities that are characteristic of CLL, which can help in confirming the diagnosis, predicting disease progression, and selecting the most effective treatment options. The IGVH mutation status is particularly important, as it can significantly influence the patient's response to certain therapies. Similarly, the TP53 mutation status is a key prognostic marker, with mutations in this gene often associated with a more aggressive disease course and resistance to standard treatments.
The cost of this comprehensive test is 9360 AED, reflecting the extensive insights it provides into the genetic landscape of CLL. By opting for this test at DNA Labs UAE, patients and healthcare providers can access crucial information that will aid in the tailored management of Chronic Lymphocytic Leukemia, potentially leading to better outcomes.
The "HLA Pre-Transplant Workup Sensitized Recipient Panel 5 Test" is a specialized diagnostic procedure offered by DNA Labs UAE, designed to assess the compatibility between organ transplant donors and recipients, with a focus on individuals who are highly sensitized. This test is crucial for identifying potential human leukocyte antigen (HLA) mismatches that could lead to transplant rejection, a common concern for sensitized recipients who have developed antibodies against foreign HLA due to previous transplants, blood transfusions, or pregnancies.
The panel involves a comprehensive screening for antibodies against HLA, providing a detailed profile that helps in the selection of a compatible donor, thereby increasing the success rate of the transplant. This advanced immunological assessment plays a pivotal role in the pre-transplant evaluation process, guiding clinicians in their decision-making to minimize the risk of acute or chronic rejection episodes.
Priced at 7800 AED, the test is conducted in the state-of-the-art facilities of DNA Labs UAE, which is equipped with the latest technologies and staffed by experienced professionals. This investment is vital for sensitized patients awaiting transplants, as it significantly enhances the likelihood of a successful outcome by facilitating the identification of a suitable donor match, ultimately improving patient survival and quality of life post-transplant.
The Non-Invasive Prenatal Paternity (NIPT) DNA Test is a groundbreaking procedure offered by DNA Labs UAE, designed to determine paternity with high accuracy during pregnancy. This test is non-invasive, meaning it poses no risk to the mother or the unborn child, as it requires only a blood sample from the expectant mother and a simple swab from the potential father. The test works by analyzing the baby's DNA found within the mother's bloodstream, comparing it to the DNA of the potential father. This advanced technology can be performed as early as the 7th week of pregnancy, providing early and reliable answers about paternity.
The cost of the NIPT Pregnancy Paternity DNA Test at DNA Labs UAE is 7000 AED. This price reflects the sophisticated technology and expertise required to accurately analyze and interpret the results. Opting for this test at DNA Labs UAE ensures a high level of accuracy, confidentiality, and professional support throughout the process. This option is particularly appealing for families seeking early paternity confirmation, without the risks associated with invasive testing methods.
The Oncomine Comprehensive Panel, along with the Oncomine Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), and PD-L1 Test, is an advanced genetic testing suite designed for a comprehensive analysis of cancer genomes. Offered by DNA Labs in the UAE, this suite of tests provides a detailed overview of the genetic alterations in tumors, aiding in the personalized treatment of cancer patients.
The Oncomine Comprehensive Panel is a next-generation sequencing (NGS) test that identifies DNA and RNA changes across a wide array of cancer-related genes. This broad-spectrum analysis helps in understanding the molecular underpinnings of an individual's cancer, facilitating targeted therapy decisions.
The Oncomine TMB test quantifies the total number of mutations within a tumor genome, providing an index of the tumor's mutation burden. A high TMB is often associated with better responses to immunotherapies, making this test crucial for therapy selection.
The MSI test assesses the status of microsatellite instability in cancer cells, which is a condition of genetic hypermutability that results from the impairment of DNA mismatch repair. MSI status is a key biomarker in certain types of cancers, such as colorectal cancer, and influences treatment choices.
The PD-L1 test measures the expression of the PD-L1 protein on the surface of tumor cells. PD-L1 is a checkpoint protein that helps cancers evade the immune system. Knowing the PD-L1 status can guide the use of checkpoint inhibitor therapies, which can be effective in treating various types of cancer.
Conducted at DNA Labs in the UAE, the comprehensive suite of these tests is priced at 24,000 AED. This investment in precision medicine can significantly impact treatment strategies, offering hope for better outcomes by tailoring therapies to the specific genetic profile of a patient's tumor.
The "Oncopro NCCN Lung Cancer Panel with PD-L1 Test" is a comprehensive diagnostic tool utilized in the assessment and management of lung cancer, adhering to the guidelines set by the National Comprehensive Cancer Network (NCCN). This advanced panel is designed to analyze a wide array of genetic markers associated with lung cancer, offering insights into the molecular profile of the tumor. This information is crucial for determining the most effective treatment strategies, including targeted therapies and immunotherapies.
A significant component of this panel is the PD-L1 test, which measures the expression of the PD-L1 protein on the surface of tumor cells. PD-L1 plays a key role in suppressing the immune system and allowing cancer cells to evade detection and destruction by immune cells. Understanding the PD-L1 status of a tumor can guide oncologists in selecting immunotherapy treatments, which can be more effective for patients with high PD-L1 expression.
The test is available at DNA Labs UAE, a leading diagnostic facility known for its state-of-the-art technology and expertise in genetic and molecular testing. The cost of the "Oncopro NCCN Lung Cancer Panel with PD-L1 Test" at DNA Labs UAE is 28,080 AED. Given the complexity and the detailed insights it provides into the genetic makeup of lung cancer, this test represents a valuable investment in personalized cancer care, enabling tailored treatment plans that can significantly improve patient outcomes.
The Sarcoma Gene Panel Test, offered at DNA Labs UAE for a cost of 22,500 AED, is a specialized genetic test designed to identify mutations in a set of genes associated with the development of sarcoma, a type of cancer that arises from transformed cells of mesenchymal origin. This comprehensive test is crucial for the accurate diagnosis, prognosis, and determination of targeted therapies for patients with sarcoma. By analyzing multiple genes simultaneously, this panel test can provide a detailed genetic profile of the tumor, helping healthcare professionals to tailor treatment plans according to the specific genetic alterations present in the cancer cells. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test is a vital tool in the fight against sarcoma, offering hope for more effective and personalized treatment options for patients.
